AR012959A1 - Composiciones de adyuvantes para vacunas, composiciones de vacunas que incluyen dichas composiciones adyuvantes, procedimiento para fabricar dichasvacunas, el uso de dichas composiciones adyuvantes en la fabricacion de medicamentos y procedimiento para estabilizar emulsiones agua-en-aceite, - Google Patents

Composiciones de adyuvantes para vacunas, composiciones de vacunas que incluyen dichas composiciones adyuvantes, procedimiento para fabricar dichasvacunas, el uso de dichas composiciones adyuvantes en la fabricacion de medicamentos y procedimiento para estabilizar emulsiones agua-en-aceite,

Info

Publication number
AR012959A1
AR012959A1 ARP980102741A ARP980102741A AR012959A1 AR 012959 A1 AR012959 A1 AR 012959A1 AR P980102741 A ARP980102741 A AR P980102741A AR P980102741 A ARP980102741 A AR P980102741A AR 012959 A1 AR012959 A1 AR 012959A1
Authority
AR
Argentina
Prior art keywords
vaccines
compositions
adjuvant compositions
stabilities
adjuvant
Prior art date
Application number
ARP980102741A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR012959A1 publication Critical patent/AR012959A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
ARP980102741A 1997-06-11 1998-06-10 Composiciones de adyuvantes para vacunas, composiciones de vacunas que incluyen dichas composiciones adyuvantes, procedimiento para fabricar dichasvacunas, el uso de dichas composiciones adyuvantes en la fabricacion de medicamentos y procedimiento para estabilizar emulsiones agua-en-aceite, AR012959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Publications (1)

Publication Number Publication Date
AR012959A1 true AR012959A1 (es) 2000-11-22

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102741A AR012959A1 (es) 1997-06-11 1998-06-10 Composiciones de adyuvantes para vacunas, composiciones de vacunas que incluyen dichas composiciones adyuvantes, procedimiento para fabricar dichasvacunas, el uso de dichas composiciones adyuvantes en la fabricacion de medicamentos y procedimiento para estabilizar emulsiones agua-en-aceite,

Country Status (17)

Country Link
EP (1) EP0999852A1 (no)
JP (1) JP2002504106A (no)
KR (1) KR20010013644A (no)
CN (1) CN1260723A (no)
AR (1) AR012959A1 (no)
AU (1) AU728759B2 (no)
BR (1) BR9810614A (no)
CA (1) CA2293444A1 (no)
CO (1) CO4940401A1 (no)
GB (1) GB9711990D0 (no)
HU (1) HUP0004001A3 (no)
IL (1) IL133126A0 (no)
NO (1) NO996133L (no)
PL (1) PL337488A1 (no)
TR (1) TR199903048T2 (no)
WO (1) WO1998056414A1 (no)
ZA (1) ZA984969B (no)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
CA2371994C (en) * 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CN1192799C (zh) * 1999-05-13 2005-03-16 惠氏控股有限公司 佐剂组合制剂
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003022248A1 (en) * 2001-09-13 2003-03-20 Korea Institute Of Science And Technology Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
JP4726485B2 (ja) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 細菌細胞壁骨格成分製剤
ES2594758T3 (es) 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Procedimientos de vacunación contra la malaria
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1755666B1 (en) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007052055A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2633772C (en) 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
JP5592110B2 (ja) 2006-07-18 2014-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2484375T3 (pl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
SG176451A1 (en) 2006-11-03 2011-12-29 Schering Plough Ltd Canine lyme disease vaccine
EP2137210B1 (en) 2007-03-02 2016-10-19 GlaxoSmithKline Biologicals SA Novel method and compositions
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
WO2009021931A1 (en) 2007-08-13 2009-02-19 Glaxosmithkline Biologicals S.A. Vaccines
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
US20100092526A1 (en) 2008-09-26 2010-04-15 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
TWI549688B (zh) 2009-06-05 2016-09-21 美國疾病傳染研究機構 合成的葡萄吡喃糖基脂質佐劑
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20130063493A (ko) 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ 백신
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP3338798A1 (en) 2011-01-06 2018-06-27 Bionor Immuno AS Multimeric peptide
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
HUE043661T2 (hu) 2011-09-16 2019-08-28 Ucb Biopharma Sprl A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
HUE044841T2 (hu) 2012-02-07 2019-11-28 Infectious Disease Res Inst TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
MY197723A (en) 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
US9982034B2 (en) 2012-10-24 2018-05-29 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10208102B2 (en) 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015077434A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
CR20160369A (es) 2014-01-21 2016-10-05 Immune Desing Corp Composiciones para uso en el tratamiento de afecciones alérgicas
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158426A1 (en) 2016-03-14 2017-09-21 University Of Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
AU2018283973A1 (en) 2017-06-11 2020-01-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3067224A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
JP7295124B2 (ja) 2017-11-03 2023-06-20 タケダ ワクチン，インコーポレイテッド ジカワクチン及び免疫原性組成物、ならびにその使用方法
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
CA2293444A1 (en) 1998-12-17
AU728759B2 (en) 2001-01-18
JP2002504106A (ja) 2002-02-05
WO1998056414A1 (en) 1998-12-17
ZA984969B (en) 1999-12-09
NO996133L (no) 2000-01-26
EP0999852A1 (en) 2000-05-17
NO996133D0 (no) 1999-12-10
BR9810614A (pt) 2000-09-12
GB9711990D0 (en) 1997-08-06
PL337488A1 (en) 2000-08-28
HUP0004001A2 (en) 2001-03-28
HUP0004001A3 (en) 2001-07-30
CO4940401A1 (es) 2000-07-24
KR20010013644A (ko) 2001-02-26
AU8336598A (en) 1998-12-30
TR199903048T2 (xx) 2000-08-21
IL133126A0 (en) 2001-03-19
CN1260723A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
AR012959A1 (es) Composiciones de adyuvantes para vacunas, composiciones de vacunas que incluyen dichas composiciones adyuvantes, procedimiento para fabricar dichasvacunas, el uso de dichas composiciones adyuvantes en la fabricacion de medicamentos y procedimiento para estabilizar emulsiones agua-en-aceite,
CA2008856C (en) Tocols as adjuvant in vaccine
DK0480982T3 (da) Tyndtflydende vacciner og bærere for aktive stoffer indeholdende en metaboliserbar olie
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
AU6210094A (en) Water-in-oil fluid vaccinal emulsions containing a metabolizable oil
HUP9901901A2 (hu) Hepatitis C elleni vakcinák
CA2296244A1 (en) Adjuvants for use in vaccines
BR9510223A (pt) Adjuvante para vacinas utilização de um polissacarideo lipidico processo para preparar uma cacina em emulsão e vacina
ES2033626T3 (es) Formulacion de adyuvante que comprende una emulsion de gota de aceite submicronica.
AR025750A1 (es) Vacunas
CO5540349A2 (es) Preparacion vacunal de virus de influenza inactivado
DK0786986T3 (da) Anvendelse af en umættet fedtalkohol
EP1097721A3 (en) Oil-based adjuvant vaccine
EP0489153A4 (en) Vaccine compositions containing liposomes
AR029081A1 (es) Una composicion de enjuague con agentes de beneficio para el cuidado del cabello y la piel en emulsion multiple' agua en aceite en agua '
DE3889521T2 (de) Impfstoff-Adjuvans.
AR011509A1 (es) Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.
FI972054A (fi) Immunogeenisiä koostumuksia
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos
RU2021106069A (ru) Адъювантная и вакцинная композиция
WO2005072679A3 (es) Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
TH1718A3 (th) เทียนจุดกันยุง

Legal Events

Date Code Title Description
FA Abandonment or withdrawal